This session will provide a learning opportunity for our audience by describing:​
J&J leaders detail how to think about managing the challenge of broadening the focus of a Medical Affairs career to encompass new and multiple therapeutic areas.
This MAPS podcast identifies potential areas for compliant collaboration by medical science liaisons with key internal Medical Affairs partners
A 2020 MAPS white paper highlights that while the metrics for departments such as R&D (new product approvals) and Commercial (sales) are clear, a single performance indicator that can measure the value of MA is lacking. While important metrics exist, such as time to publication submission and customer satisfaction, Share of Scientific Voice (SoSV) measures scientific impact and can serve as an objective and strategic performance metric for MA.
The measurement of SoSV is derived from the number of relevant mentions across scientific disseminations, relative to alternatives in the same therapeutic area. These clear outputs correlate with several activities that MA professionals lead across the MAPS-defined key pillars for MA - insights, evidence generation and evidence dissemination. This work is highly strategic and valuable for an organisation, as it shapes product strategy, closes data gaps, forms the scientific narrative and educates healthcare professionals. Therefore, SoSV provides a valuable metric for the performance and progress of MA.
This webinar will review the rationale for SoSV as a performance metric in MA, how it is implemented in practice, and examine how it can be used strategically to measure, prioritize and achieve success.
This report shares the key insights from a MAPS special session on Field Medical engagement and provides further context from Medical Affairs colleagues who have first-hand knowledge of the ever-changing Field Medical role.
The objective of this podcast is to discuss how the 21st Century Cures Act has led to new initiatives at FDA involving Real World Evidence.
MAPS speaks with co-leads of the Insights Focus Area Working Group (FAWG) about the current state and future directions for Insights in Medical Affairs.
This 8th episode in our Field Medical podcast series explores the evolving roles of MSLs in the context of clinical trials.
Events of the last 12 months have driven the pharmaceutical industry to more comprehensively examine how it can address ethnic and racial disparities in health outcomes and clinical research access. It is well accepted that diversity of clinical trial participants is essential to ensure that the trial population is truly representative of the patients who will use the therapy, yet disparities in clinical trial participation remain. A multi-faceted approach is required to understand the critical barriers to clinical research access for patients from diverse backgrounds.
During this thought-provoking webinar, our panel of internationally renowned Patient Advisors and Diversity Experts will share their perspectives on diverse representation in clinical trials and key barriers to research access, and explore solutions to address these critical issues.
This program will:
• Define health economics and outcomes research (HEOR) and its relationship to Medical Affairs
• Understand HEOR professional competencies included in the ISPOR Competency Framework, and which are most relevant to Medical Affairs professionals
• Discuss potential applications of the competencies by different stakeholders (employers, new professionals, students, academia)
• Identify ways for Medical Affairs professionals to further their HEOR knowledge and skills